| P2093 | author name string | Y Ito | |
| | M Gotoh | |
| | K Ohyashiki | |
| | S Okabe | |
| | M Asano | |
| | T Kitahara | |
| | S Katagiri | |
| | S Yoshizawa | |
| | T Tauchi | |
| | T Suguro | |
| | D Akahane | |
| P2860 | cites work | Human herpesvirus 6 DNA in plasma after allogeneic stem cell transplantation: incidence and clinical significance. | Q53646005 |
| | The impact of human herpesvirus 6B reactivation on early complications following allogeneic hematopoietic stem cell transplantation. | Q54574205 |
| | Thrombotic microangiopathy in transplantation and malignancy | Q33369772 |
| | The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade | Q34195684 |
| | Cytomegalovirus prophylaxis and treatment after hematopoietic stem cell transplantation in Canada: a description of current practices and comparison with Centers for Disease Control/Infectious Diseases Society of America/American Society for Blood a | Q35757719 |
| | Human herpesvirus 6 infection after hematopoietic cell transplantation: is routine surveillance necessary? | Q35774717 |
| | Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation | Q36095851 |
| | Early human herpesvirus type 6 reactivation after allogeneic stem cell transplantation: a large-scale clinical study. | Q40300472 |
| | Human herpesvirus 6 infection of the gastroduodenal mucosa | Q40429920 |
| | Human herpesvirus-6 and -7 in pediatric stem cell transplantation. | Q40515277 |
| | The best endpoint for acute GVHD treatment trials | Q43100931 |
| | Infections with human herpesvirus 6 variant B delay platelet engraftment after allogeneic haematopoietic stem cell transplantation | Q43715359 |
| | Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation | Q43796854 |
| | Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation | Q44012475 |
| | Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate | Q44094549 |
| | Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. | Q44189939 |
| | Endothelial damage caused by cytomegalovirus and human herpesvirus-6. | Q44383243 |
| | Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group | Q44393577 |
| | Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation | Q45227888 |
| | Human herpes virus 6 plasma DNA positivity after hematopoietic stem cell transplantation in children: an important risk factor for clinical outcome. | Q45394548 |
| | Time-related changes in the incidence, severity, and clinical outcome of hepatic veno-occlusive disease in hematopoietic stem cell transplantation patients during the past 10 years | Q46554380 |
| | Detection of herpesvirus DNA in the serum of immunocompetent children | Q50109685 |
| | Human herpesvirus 6 infection after allogeneic stem cell transplantation: incidence, outcome, and factors associated with HHV-6 reactivation. | Q50864903 |
| | Risk factors for developing human herpesvirus 6 (HHV-6) reactivation after allogeneic hematopoietic stem cell transplantation and its association with central nervous system disorders. | Q53577416 |
| P433 | issue | 3 | |
| P921 | main subject | Human herpesvirus 6 | Q6974 |
| P304 | page(s) | 440-449 | |
| P577 | publication date | 2014-05-09 | |
| P1433 | published in | Transplant Infectious Disease | Q15749562 |
| P1476 | title | Human herpesvirus 6 reactivation on the 30th day after allogeneic hematopoietic stem cell transplantation can predict grade 2-4 acute graft-versus-host disease | |
| P478 | volume | 16 | |